CA3198721A1 - Radioactive complexes of anti-her2 antibody, and radiopharmaceutical - Google Patents
Radioactive complexes of anti-her2 antibody, and radiopharmaceuticalInfo
- Publication number
- CA3198721A1 CA3198721A1 CA3198721A CA3198721A CA3198721A1 CA 3198721 A1 CA3198721 A1 CA 3198721A1 CA 3198721 A CA3198721 A CA 3198721A CA 3198721 A CA3198721 A CA 3198721A CA 3198721 A1 CA3198721 A1 CA 3198721A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- group
- peptide
- chelating agent
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020174840 | 2020-10-16 | ||
| JP2020-174840 | 2020-10-16 | ||
| JP2020-215740 | 2020-12-24 | ||
| JP2020215740 | 2020-12-24 | ||
| JP2021-024688 | 2021-02-18 | ||
| JP2021024688 | 2021-02-18 | ||
| PCT/JP2021/038207 WO2022080481A1 (ja) | 2020-10-16 | 2021-10-15 | 抗her2抗体の放射性複合体、及び、放射性医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3198721A1 true CA3198721A1 (en) | 2022-04-21 |
Family
ID=81208085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3198721A Pending CA3198721A1 (en) | 2020-10-16 | 2021-10-15 | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230390425A1 (https=) |
| EP (1) | EP4230637A4 (https=) |
| JP (1) | JPWO2022080481A1 (https=) |
| KR (1) | KR20230088764A (https=) |
| AU (1) | AU2021361746A1 (https=) |
| CA (1) | CA3198721A1 (https=) |
| IL (1) | IL302111A (https=) |
| MX (1) | MX2023004428A (https=) |
| TW (1) | TW202233247A (https=) |
| WO (1) | WO2022080481A1 (https=) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES3058443T3 (es) | 2015-05-20 | 2026-03-10 | Univ Kagoshima | Modificación específica de anticuerpo con péptido de unión a IgG |
| DK3470418T3 (da) * | 2016-06-13 | 2024-09-30 | Univ Kagoshima | Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid |
| JP7291395B2 (ja) | 2017-06-16 | 2023-06-15 | 国立大学法人 鹿児島大学 | IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
| BR112020012099A2 (pt) * | 2017-12-18 | 2020-11-17 | Janssen Biotech, Inc. | radiomarcação de polipeptídeos |
| SG11202009990UA (en) * | 2018-04-16 | 2020-11-27 | Nihon Mediphysics Co Ltd | Modified antibody and radioactive metal-labelled antibody |
| JP2020021574A (ja) | 2018-07-30 | 2020-02-06 | パナソニックIpマネジメント株式会社 | 光源ユニット、照明器具、及び照明器具用の拡張構造 |
| JP2020174840A (ja) | 2019-04-17 | 2020-10-29 | 豊丸産業株式会社 | 遊技機 |
| JP7272895B2 (ja) | 2019-08-02 | 2023-05-12 | 清水建設株式会社 | 水平搬送台車 |
| IL292133A (en) * | 2019-10-18 | 2022-06-01 | Nihon Mediphysics Co Ltd | Ri-labeled humanized antibody |
| JPWO2021075546A1 (https=) * | 2019-10-18 | 2021-04-22 | ||
| TWI886164B (zh) | 2019-10-24 | 2025-06-11 | 國立大學法人鹿兒島大學 | 1價ccap生成物之製造方法 |
| WO2022149578A1 (ja) * | 2021-01-08 | 2022-07-14 | 日本メジフィジックス株式会社 | Ac-225溶液の製造方法およびAc-225溶液を用いた医薬の製造方法 |
| EP4397320A1 (en) * | 2021-08-31 | 2024-07-10 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product |
-
2021
- 2021-10-15 US US18/249,220 patent/US20230390425A1/en active Pending
- 2021-10-15 JP JP2022557474A patent/JPWO2022080481A1/ja active Pending
- 2021-10-15 IL IL302111A patent/IL302111A/en unknown
- 2021-10-15 TW TW110138421A patent/TW202233247A/zh unknown
- 2021-10-15 KR KR1020237016275A patent/KR20230088764A/ko active Pending
- 2021-10-15 MX MX2023004428A patent/MX2023004428A/es unknown
- 2021-10-15 EP EP21880216.3A patent/EP4230637A4/en active Pending
- 2021-10-15 CA CA3198721A patent/CA3198721A1/en active Pending
- 2021-10-15 WO PCT/JP2021/038207 patent/WO2022080481A1/ja not_active Ceased
- 2021-10-15 AU AU2021361746A patent/AU2021361746A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4230637A1 (en) | 2023-08-23 |
| US20230390425A1 (en) | 2023-12-07 |
| IL302111A (en) | 2023-06-01 |
| WO2022080481A1 (ja) | 2022-04-21 |
| EP4230637A4 (en) | 2025-12-17 |
| KR20230088764A (ko) | 2023-06-20 |
| AU2021361746A1 (en) | 2023-06-22 |
| MX2023004428A (es) | 2023-05-04 |
| AU2021361746A9 (en) | 2024-06-27 |
| TW202233247A (zh) | 2022-09-01 |
| JPWO2022080481A1 (https=) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2654803B1 (en) | Radiolabeled her2-binding peptide conjugates | |
| TWI875842B (zh) | 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體 | |
| JP2025121972A (ja) | Ri標識されたヒト化抗体 | |
| EP4397320A1 (en) | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product | |
| WO2023277144A1 (ja) | Heg1タンパク質に結合するヒト化抗体および当該抗体と放射性核種との複合体 | |
| EP4609881A1 (en) | Radioactive pharmaceutical composition | |
| CN116456992A (zh) | 抗her2抗体的放射性复合物和放射性药物 | |
| US20230390425A1 (en) | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical | |
| US20240207464A1 (en) | Radioactive complex of anti-cd20 antibody, and radiopharmaceutical | |
| US20240207463A1 (en) | Radioactive complex of anti-egfr antibody, and radiopharmaceutical | |
| US20250152760A1 (en) | Radioactive complex of anti-vegf antibody, and radiopharmaceutical | |
| EA051630B1 (ru) | Радиоактивные комплексы анти-her2 антитела и радиофармацевтическое средство | |
| HK40092772A (zh) | 抗her2抗体的放射性复合物和放射性药物 | |
| EA050335B1 (ru) | Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство | |
| EP4328244A1 (en) | Humanised antibodies labelled with radionuclides that emit ?-rays | |
| CN117377690A (zh) | 抗egfr抗体的放射性复合物和放射性药物 | |
| CN117769440A (zh) | 抗cd20抗体的放射性复合物和放射性药物 | |
| EA050695B1 (ru) | Способ получения антитела, меченного радиоактивным металлом | |
| WO2011110490A1 (en) | Process for the production of radioactively labelled scfv antibody fragments, kits and compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250930 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250930 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251003 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251003 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251201 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251222 |